Home » Newsletters » BioWorld Science

BioWorld Science

March 29, 2017

View Archived Issues

Allergan and Paratek announce results from phase III trials of sarecycline in acne

EMA committee recommends approval of dinutuximab beta for the treatment of high-risk neuroblastoma

EC-70124 inhibits NF-kappa-B and STAT3 and reduces tumor growth in prostate cancer xenografts

Final Pazotest-01 data show transient activity of pazopanib in chemoresistant germ cell tumors

EpiAxis Therapeutics describes pipeline activity at BIO-Europe Spring

Cellceutix presents phase II interim analysis for brilacidin in severe oral mucositis

Perrigo completes divestiture of Tysabri royalty stream rights

Millendo Therapeutics initiates phase II trial of ATR-101 in endogenous Cushing's syndrome

3M-052 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine

FDA grants priority review to Lynparza NDA

Immune-Onc Therapeutics signs license agreement for cancer immunotherapy

Shionogi submits NDA in Japan for pediatric use of S-524101

FDA approves Ocrevus for relapsing and primary progressive forms of MS

Tadalafil shows efficacy in the treatment of Peyronie's disease

FDA approves Dupixent for moderate to severe atopic dermatitis

Mitsubishi Tanabe Pharma and Daiichi Sankyo expand diabetes alliance to cover MT-2412

Janssen Pharmaceutica NV patents compounds for treating pain

Jubilant Biosys discovers bromodomain-containing protein 4 inhibitors

Cephalon identifies new chlorokynurenines

Tonix initiates phase III HONOR trial of TNX-102 SL for post-traumatic stress disorder

Basilea Pharmaceutica AG discovers bacterial efflux pump inhibitors

Calithera achieves milestone with CB-1158 under Incyte collaboration

Boehringer Ingelheim Pharma GmbH & Co. KG patents tyrosine-protein kinase SYK inhibitors

Cara Therapeutics reports topline data from Part A of phase II/III trial of CR-845

Cempra withdraws solithromycin MAA in Europe with plans to resubmit

Ritter reports phase IIb/III topline data on RP-G28 for lactose intolerance

Replicel's phase I/II tendon repair study of RCT-01 meets primary endpoint

Bristol-Myers Squibb, Parker Institute and Cancer Research Institute collaborate in immuno-oncology

Numares and Oxford University collaborate to develop in vitro diagnostic test for use in MS

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...